Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03399513
Title Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma (R-CHOEP-brut)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Hospital Muenster
Indications

diffuse large B-cell lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Etoposide + Ibrutinib + Prednisolone + Rituximab + Vincristine Sulfate

Age Groups: adult
Covered Countries DEU

Facility Status City State Zip Country Details
HELIOS Hospital Berlin-Buch Recruiting Berlin 13125 Germany Details
Hospital Chemnitz Recruiting Chemnitz 09116 Germany Details
University Hospital Cologne Recruiting Cologne 50937 Germany Details
University Hospital Göttingen Terminated Göttingen 37075 Germany Details
University Hospital Hamburg-Eppendorf Recruiting Hamburg 20246 Germany Details
University Hospital Heidelberg Recruiting Heidelberg 69120 Germany Details
Saarland University Hospital Terminated Homburg 66421 Germany Details
Johannes Wesling Hospital Minden Recruiting Minden 32429 Germany Details
University Hospital Muenster Recruiting Muenster 48149 Germany Details
Rostock University Medical Center Recruiting Rostock 18057 Germany Details
University Hospital Tuebingen Recruiting Tuebingen 72076 Germany Details
University Hospital Ulm Recruiting Ulm 89081 Germany Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field